Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Regeneron Pharmaceuticals (REGN)

Nasdaq Health Care Biotechnology S&P 500Nasdaq-100
$904.35
+1.45 (+0.16%)
Close of Nov 06, 2026 · end-of-day data
Source: Regeneron Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 02, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$4.86B$5.87B$5.15B$6.56B$8.50B$16.07B$12.17B$13.12B$14.20B$14.34B
Cost of revenue$194.62M$202.51M$237.50M$402.80M——————
Gross profit$4.67B$5.67B$4.91B$6.15B——————
Research & development$2.05B$2.08B$1.47B$2.45B$2.65B$2.86B$3.59B$4.44B$5.13B$5.85B
Selling, general & admin$1.18B$1.32B$1.13B$1.34B$1.35B$1.82B$2.12B$2.63B$2.95B$2.70B
Operating income$1.33B$2.08B$2.53B$2.21B$3.58B$8.95B$4.74B$4.05B$3.99B$3.58B
Interest expense$7.20M$25.10M$28.20M$30.20M$56.90M$57.30M$59.40M$73.00M$55.20M$43.80M
Pre-tax income$1.33B$2.08B$2.55B$2.43B$3.81B$9.33B$4.86B$4.20B$4.78B$5.23B
Income tax$434.30M$880.00M$109.10M$313.30M$297.20M$1.25B$520.40M$245.70M$367.30M$725.80M
Net income$895.50M$1.20B$2.44B$2.12B$3.51B$8.08B$4.34B$3.95B$4.41B$4.50B
EBITDA$1.44B$2.23B$2.68B$2.42B$3.81B$9.23B$5.08B$4.47B$4.47B$4.12B
EPS (basic)$8.55$11.27$22.65$19.38$32.65$76.40$40.51$37.05$40.90$43.07
EPS (diluted)$7.70$10.34$21.29$18.46$30.52$71.97$38.22$34.77$38.34$41.48
Diluted shares116.30M115.90M114.80M114.60M115.10M112.20M113.50M113.70M115.10M108.60M
Gross margin96.0%96.6%95.4%93.9%——————
Operating margin27.4%35.4%49.3%33.7%42.1%55.7%38.9%30.9%28.1%24.9%
Net margin18.4%20.4%47.5%32.3%41.3%50.2%35.6%30.1%31.1%31.4%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$535.20M$812.70M$1.47B$1.62B$2.19B$2.89B$3.11B$2.73B$2.49B$3.12B
Short-term investments$503.48M$596.80M$1.34B$1.60B$1.39B$2.81B$4.64B$8.11B$6.52B$5.49B
Receivables$1.34B$1.54B$1.72B$2.10B$4.11B$6.04B$5.33B$5.67B$6.21B$5.74B
Inventory$399.36M$726.10M$1.15B$1.42B$1.92B$1.95B$2.40B$2.58B$3.09B$3.20B
Total current assets$3.18B$4.33B$6.45B$7.69B$9.78B$14.01B$15.88B$19.48B$18.66B$18.02B
Total assets$6.97B$8.76B$11.73B$14.81B$17.16B$25.43B$29.21B$33.08B$37.76B$40.56B
Total current liabilities$1.24B$1.14B$1.44B$2.10B$2.70B$3.93B$3.14B$3.42B$3.94B$4.37B
Short-term debt———$0——————
Long-term debt———$0$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B
Total debt———$0$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B
Total liabilities$2.52B$2.62B$2.98B$3.72B$6.14B$6.67B$6.55B$7.11B$8.41B$9.30B
Shareholders' equity$4.45B$6.14B$8.76B$11.09B$11.03B$18.77B$22.66B$25.97B$29.35B$31.26B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$1.49B$1.31B$2.20B$2.43B$2.62B$7.08B$5.01B$4.59B$4.42B$4.98B
Capital expenditures$511.90M$272.60M$383.10M$429.60M$614.60M$551.90M$590.10M$718.60M$755.90M$898.40M
Free cash flow$974.00M$1.03B$1.81B$2.00B$2.00B$6.53B$4.42B$3.88B$3.66B$4.08B
Investing cash flow-$1.05B-$1.01B-$1.46B-$2.03B-$70.60M-$5.38B-$3.78B-$3.19B-$2.47B-$629.10M
Financing cash flow-$700.50M-$24.40M-$77.10M-$252.10M-$1.97B-$1.01B-$1.01B-$1.79B-$2.20B-$3.72B
Dividends paid———————$0$0$370.30M
Share buybacks$0$0$4.40M$275.90M$5.85B$1.65B$2.08B$2.23B$2.60B$3.44B
Stock-based compensation$559.90M$507.30M$427.40M$464.30M$432.00M$601.70M$725.00M$885.00M$982.80M$993.70M
Depreciation & amortization$104.70M$145.50M$148.20M$210.30M$235.90M$286.20M$341.40M$421.00M$482.90M$543.70M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.